1. Scrip
  2. >>Focus On Asia
  3. >>India

Davinder Gill On Researching Low-Cost Vaccines: An Interview With PharmAsia News (Part 2 of 2)

 
• By Vikas Dandekar

Davinder Gill provides an update on the sharpened focus of the New Delhi-based MSD-Wellcome Trust Hilleman Laboratories as it seeks to narrow its research and development focus in developing vaccines for low-income emerging markets.

MUMBAI - Davinder Gill is the chief executive officer of MSD-Wellcome Trust Hilleman Laboratories non-profit joint venture by Merck Sharp & Dohme Ltd. and the Wellcome Foundation Ltd., which has moved quickly on plans for a makeover at the New Delhi-based research organization to focus leads in enteric diseases, a departure from a broad search for preventive vaccines in diverse disease areas like human papilloma virus, dengue and rotavirus ([A#28140404007]).

The aim is still to develop vaccines for low income countries and Gill, a chemical engineer from Houston and alumni...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 
• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now